Dr Douglas Eugene Kaylor, DDS | |
1406 Bailey Ave, Suite F, Needles, CA 92363-3115 | |
(760) 326-4541 | |
(760) 326-3844 |
Full Name | Dr Douglas Eugene Kaylor |
---|---|
Gender | Female |
Speciality | Dentist - General Practice |
Location | 1406 Bailey Ave, Needles, California |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1710056205 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
1223G0001X | Dentist - General Practice | 28581 (California) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Douglas Eugene Kaylor, DDS 1406 Bailey Ave, Suite F, Needles, CA 92363-3115 Ph: (760) 326-4541 | Dr Douglas Eugene Kaylor, DDS 1406 Bailey Ave, Suite F, Needles, CA 92363-3115 Ph: (760) 326-4541 |
News Archive
Since she was a baby, Carleen Trautz's left eye turned outward, rather than looking straight ahead, and it made her life miserable.
Despite Republicans' resistance to the federal health law, the percentage of Americans without health insurance in 2017 remained the same as during the last year of the Obama administration, according to a closely watched report from the Census Bureau released Wednesday.
The American Joint Replacement Registry (AJRR) has selected Remedy Informatics, the leading provider of registries for Life Science, to build a registry to collect data on all primary and revision total joint replacement procedures in the United States. Representatives from AJRR and Remedy Informatics will unveil the new registry at the American Association of Orthopaedic Surgeons (AAOS) Annual Meeting in San Francisco, Feb. 7 – Feb. 11.
A research collaboration between the Wyss Institute for Biologically Inspired Engineering at Harvard University and Children's Hospital Boston has developed "smart" injectable nanotherapeutics that can be programmed to selectively deliver drugs to the cells of the pancreas. Although this nanotechnology will need significant additional testing and development before being ready for clinical use, it could potentially improve treatment for Type I diabetes by increasing therapeutic efficacy and reducing side effects.
Statistics from the Centers for Disease Control and Prevention (CDC) rank mortality related to chronic liver disease and cirrhosis as the 12th most common cause of death in adults in the U.S. Using a modified definition that includes diseases such as viral hepatitis, liver cancer and obesity-related fatty liver disease, Mayo Clinic-led researchers have found that liver-related mortality is as high as fourth for some age groups, and eighth overall.
› Verified 5 days ago